Alto Neuroscience, Inc. (ANRO)
19.68
-1.47
(-6.95%)
USD |
NYSE |
Jun 10, 16:00
19.74
+0.06
(+0.30%)
Pre-Market: 20:00
Alto Neuroscience SG&A Expense (Quarterly) : 6.844M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 6.844M |
| December 31, 2025 | 5.059M |
| September 30, 2025 | 4.426M |
| June 30, 2025 | 5.558M |
| March 31, 2025 | 5.702M |
| December 31, 2024 | 6.197M |
| September 30, 2024 | 5.826M |
| Date | Value |
|---|---|
| June 30, 2024 | 5.157M |
| March 31, 2024 | 4.434M |
| December 31, 2023 | 2.122M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 2.053M |
| March 31, 2023 | 1.592M |
| December 31, 2022 | 1.736M |
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Johnson & Johnson | 6.034B |
| Eli Lilly & Co. | 2.934B |
| Bristol Myers Squibb Co. | 1.617B |
| NRX Pharmaceuticals, Inc. | 3.813M |
| LB Pharmaceuticals, Inc. | 7.459M |